Secondary Prevention in ACS: The Role of Novel Oral Anticoagulants View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2013-08-14

AUTHORS

Hyun-Jae Kang , Matthew T. Roe

ABSTRACT

Currently available oral antithrombotic treatments for secondary prevention of acute coronary syndrome are aspirin, ticlopidine, clopidogrel, warfarin, prasugrel and ticagrelor. Recently new oral anticoagulants have been evaluated in this field. Among them, rivaroxaban has shown to reduce cardiovascular events of patients with acute coronary syndrome (ACS) in a large phase III trial. However, the addition of anticoagulants to antiplatelet therapies has been consistently associated with an increased risk of bleeding. To justify use of oral anticoagulants for secondary prevention of ACS, net clinical benefit should outweigh additional risk of adverse reactions, mostly bleeding, and the costs of new oral anticoagulants. The role of novel oral anticoagulants should be determined in the context of combination or comparison with new potent P2Y12 inhibitors. More... »

PAGES

123-138

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4471-5424-2_4

DOI

http://dx.doi.org/10.1007/978-1-4471-5424-2_4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007724064


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7463, 27705, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7463, 27705, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kang", 
        "givenName": "Hyun-Jae", 
        "id": "sg:person.01254550333.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254550333.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7035, 27705, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7035, 27705, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roe", 
        "givenName": "Matthew T.", 
        "id": "sg:person.0674336554.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674336554.45"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2013-08-14", 
    "datePublishedReg": "2013-08-14", 
    "description": "Currently available oral antithrombotic treatments for secondary prevention of acute coronary syndrome are aspirin, ticlopidine, clopidogrel, warfarin, prasugrel and ticagrelor. Recently new oral anticoagulants have been evaluated in this field. Among them, rivaroxaban has shown to reduce cardiovascular events of patients with acute coronary syndrome (ACS) in a large phase III trial. However, the addition of anticoagulants to antiplatelet therapies has been consistently associated with an increased risk of bleeding. To justify use of oral anticoagulants for secondary prevention of ACS, net clinical benefit should outweigh additional risk of adverse reactions, mostly bleeding, and the costs of new oral anticoagulants. The role of novel oral anticoagulants should be determined in the context of combination or comparison with new potent P2Y12 inhibitors.", 
    "editor": [
      {
        "familyName": "Avanzas", 
        "givenName": "Pablo", 
        "type": "Person"
      }, 
      {
        "familyName": "Clemmensen", 
        "givenName": "Peter", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4471-5424-2_4", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4471-5423-5", 
        "978-1-4471-5424-2"
      ], 
      "name": "Pharmacological Treatment of Acute Coronary Syndromes", 
      "type": "Book"
    }, 
    "keywords": [
      "acute coronary syndrome", 
      "new oral anticoagulants", 
      "novel oral anticoagulants", 
      "oral anticoagulants", 
      "secondary prevention", 
      "coronary syndrome", 
      "new potent P2Y12 inhibitors", 
      "large phase III trials", 
      "oral antithrombotic treatment", 
      "potent P2Y12 inhibitors", 
      "phase III trials", 
      "net clinical benefit", 
      "addition of anticoagulants", 
      "antithrombotic treatment", 
      "P2Y12 inhibitors", 
      "cardiovascular events", 
      "antiplatelet therapy", 
      "clinical benefit", 
      "adverse reactions", 
      "anticoagulants", 
      "additional risk", 
      "context of combinations", 
      "prevention", 
      "syndrome", 
      "risk", 
      "clopidogrel", 
      "prasugrel", 
      "ticagrelor", 
      "rivaroxaban", 
      "ticlopidine", 
      "aspirin", 
      "patients", 
      "warfarin", 
      "therapy", 
      "trials", 
      "treatment", 
      "role", 
      "inhibitors", 
      "benefits", 
      "events", 
      "use", 
      "combination", 
      "addition", 
      "comparison", 
      "reaction", 
      "cost", 
      "context", 
      "field", 
      "available oral antithrombotic treatments", 
      "III trial"
    ], 
    "name": "Secondary Prevention in ACS: The Role of Novel Oral Anticoagulants", 
    "pagination": "123-138", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007724064"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4471-5424-2_4"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4471-5424-2_4", 
      "https://app.dimensions.ai/details/publication/pub.1007724064"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_181.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4471-5424-2_4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4471-5424-2_4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4471-5424-2_4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4471-5424-2_4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4471-5424-2_4'


 

This table displays all metadata directly associated to this object as RDF triples.

124 TRIPLES      23 PREDICATES      75 URIs      68 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4471-5424-2_4 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author Na7545bd9eefc4cf3bfe8a0d271b7d1eb
4 schema:datePublished 2013-08-14
5 schema:datePublishedReg 2013-08-14
6 schema:description Currently available oral antithrombotic treatments for secondary prevention of acute coronary syndrome are aspirin, ticlopidine, clopidogrel, warfarin, prasugrel and ticagrelor. Recently new oral anticoagulants have been evaluated in this field. Among them, rivaroxaban has shown to reduce cardiovascular events of patients with acute coronary syndrome (ACS) in a large phase III trial. However, the addition of anticoagulants to antiplatelet therapies has been consistently associated with an increased risk of bleeding. To justify use of oral anticoagulants for secondary prevention of ACS, net clinical benefit should outweigh additional risk of adverse reactions, mostly bleeding, and the costs of new oral anticoagulants. The role of novel oral anticoagulants should be determined in the context of combination or comparison with new potent P2Y12 inhibitors.
7 schema:editor N048880906d9f41e0bded4a0c19b85c73
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N91cdbeaa0c05465aa5425697f8508259
12 schema:keywords III trial
13 P2Y12 inhibitors
14 acute coronary syndrome
15 addition
16 addition of anticoagulants
17 additional risk
18 adverse reactions
19 anticoagulants
20 antiplatelet therapy
21 antithrombotic treatment
22 aspirin
23 available oral antithrombotic treatments
24 benefits
25 cardiovascular events
26 clinical benefit
27 clopidogrel
28 combination
29 comparison
30 context
31 context of combinations
32 coronary syndrome
33 cost
34 events
35 field
36 inhibitors
37 large phase III trials
38 net clinical benefit
39 new oral anticoagulants
40 new potent P2Y12 inhibitors
41 novel oral anticoagulants
42 oral anticoagulants
43 oral antithrombotic treatment
44 patients
45 phase III trials
46 potent P2Y12 inhibitors
47 prasugrel
48 prevention
49 reaction
50 risk
51 rivaroxaban
52 role
53 secondary prevention
54 syndrome
55 therapy
56 ticagrelor
57 ticlopidine
58 treatment
59 trials
60 use
61 warfarin
62 schema:name Secondary Prevention in ACS: The Role of Novel Oral Anticoagulants
63 schema:pagination 123-138
64 schema:productId N679c5d2486b747cbac2320376c891cca
65 Ne04738556dc542d3a40de826cb3b61a5
66 schema:publisher N1d8f61b77f6f47b3855734a3ed9c5eb4
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007724064
68 https://doi.org/10.1007/978-1-4471-5424-2_4
69 schema:sdDatePublished 2022-01-01T19:10
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher Nb41d896965a54c7e8a713bd678fe8421
72 schema:url https://doi.org/10.1007/978-1-4471-5424-2_4
73 sgo:license sg:explorer/license/
74 sgo:sdDataset chapters
75 rdf:type schema:Chapter
76 N048880906d9f41e0bded4a0c19b85c73 rdf:first Ne67a2970927142b49bfe0253a9361614
77 rdf:rest N680bf527305b4f1a8166f0dd88bd2e13
78 N1d8f61b77f6f47b3855734a3ed9c5eb4 schema:name Springer Nature
79 rdf:type schema:Organisation
80 N1df39bc6e14f4707b249eb3b5f163874 schema:familyName Clemmensen
81 schema:givenName Peter
82 rdf:type schema:Person
83 N679c5d2486b747cbac2320376c891cca schema:name dimensions_id
84 schema:value pub.1007724064
85 rdf:type schema:PropertyValue
86 N680bf527305b4f1a8166f0dd88bd2e13 rdf:first N1df39bc6e14f4707b249eb3b5f163874
87 rdf:rest rdf:nil
88 N7898bfb3fa2345468542a2eecb77dc60 rdf:first sg:person.0674336554.45
89 rdf:rest rdf:nil
90 N91cdbeaa0c05465aa5425697f8508259 schema:isbn 978-1-4471-5423-5
91 978-1-4471-5424-2
92 schema:name Pharmacological Treatment of Acute Coronary Syndromes
93 rdf:type schema:Book
94 Na7545bd9eefc4cf3bfe8a0d271b7d1eb rdf:first sg:person.01254550333.69
95 rdf:rest N7898bfb3fa2345468542a2eecb77dc60
96 Nb41d896965a54c7e8a713bd678fe8421 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 Ne04738556dc542d3a40de826cb3b61a5 schema:name doi
99 schema:value 10.1007/978-1-4471-5424-2_4
100 rdf:type schema:PropertyValue
101 Ne67a2970927142b49bfe0253a9361614 schema:familyName Avanzas
102 schema:givenName Pablo
103 rdf:type schema:Person
104 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
105 schema:name Medical and Health Sciences
106 rdf:type schema:DefinedTerm
107 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
108 schema:name Cardiorespiratory Medicine and Haematology
109 rdf:type schema:DefinedTerm
110 sg:person.01254550333.69 schema:affiliation grid-institutes:grid.26009.3d
111 schema:familyName Kang
112 schema:givenName Hyun-Jae
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254550333.69
114 rdf:type schema:Person
115 sg:person.0674336554.45 schema:affiliation grid-institutes:grid.26009.3d
116 schema:familyName Roe
117 schema:givenName Matthew T.
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674336554.45
119 rdf:type schema:Person
120 grid-institutes:grid.26009.3d schema:alternateName Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7035, 27705, Durham, NC, USA
121 Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7463, 27705, Durham, NC, USA
122 schema:name Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7035, 27705, Durham, NC, USA
123 Division of Cardiology, Duke Clinical Research Institute, 2400 Pratt St., Rm. 7463, 27705, Durham, NC, USA
124 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...